Eton Pharmaceuticals, Inc. Income Tax Expense
Eton Pharmaceuticals, Inc. (ETON) reported Income Tax Expense of $140.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. income tax expense (benefit) for the quarter ending 2026-06-30 was $140.00K, a 112.12% increase year-over-year.
- Eton Pharmaceuticals, Inc. income tax expense (benefit) for the quarter ending 2026-03-31 was $20.00K, a 72.97% decline year-over-year.
- Eton Pharmaceuticals, Inc. income tax expense (benefit) for the quarter ending 2025-12-31 was -$69.00K, a 179.31% decline year-over-year.
- Eton Pharmaceuticals, Inc. income tax expense (benefit) for the quarter ending 2025-09-30 was -$28.00K.
- Eton Pharmaceuticals, Inc. income tax expense (benefit) for fiscal 2025 was $43.00K, a 186.67% increase from fiscal 2024.
- Eton Pharmaceuticals, Inc. income tax expense (benefit) for fiscal 2024 was $15.00K, a 93.93% decline from fiscal 2023.
- Eton Pharmaceuticals, Inc. income tax expense (benefit) for fiscal 2023 was $247.00K.
- Eton Pharmaceuticals, Inc. income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $140.00K 10-Q · filed 2026-08-13 | $160.00K 10-Q · filed 2026-08-13 | $91.00K derived: sum of 3 quarters · filed 2026-08-13 | $63.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $20.00K 10-Q · filed 2026-05-14 | -$49.00K derived: sum of 2 quarters · filed 2026-05-14 | -$77.00K derived: sum of 3 quarters · filed 2026-05-14 | -$11.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$97.00K derived: sum of 2 quarters · filed 2026-03-19 | -$31.00K derived: sum of 3 quarters · filed 2026-08-13 | $43.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | -$28.00K 10-Q · filed 2025-11-06 | $38.00K derived: sum of 2 quarters · filed 2026-08-13 | $112.00K 10-Q · filed 2025-11-06 | $199.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $66.00K 10-Q · filed 2026-08-13 | $140.00K 10-Q · filed 2026-08-13 | $227.00K derived: sum of 3 quarters · filed 2026-08-13 | $101.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $74.00K 10-Q · filed 2026-05-14 | $161.00K derived: sum of 2 quarters · filed 2026-05-14 | $35.00K derived: sum of 3 quarters · filed 2026-05-14 | $89.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$39.00K derived: sum of 2 quarters · filed 2026-03-19 | $15.00K derived: sum of 3 quarters · filed 2026-03-19 | $15.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | -$126.00K 10-Q · filed 2025-11-06 | -$72.00K derived: sum of 2 quarters · filed 2025-11-06 | -$72.00K 10-Q · filed 2025-11-06 | $175.00K derived: sum of 4 quarters · filed 2026-03-19 |
| 2024-06-30 | $54.00K 10-Q · filed 2025-08-07 | $54.00K 10-Q · filed 2025-08-07 | $301.00K derived: sum of 3 quarters · filed 2026-03-19 | $301.00K derived: sum of 4 quarters · filed 2026-03-19 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 | $247.00K derived: sum of 2 quarters · filed 2026-03-19 | $247.00K derived: sum of 3 quarters · filed 2026-03-19 | $247.00K derived: sum of 4 quarters · filed 2026-03-19 |
| 2023-12-31 | $247.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $247.00K derived: sum of 2 quarters · filed 2026-03-19 | $247.00K derived: sum of 3 quarters · filed 2026-03-19 | $247.00K 10-K · filed 2026-03-19 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 4 quarters · filed 2025-03-18 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-03-18 | $0.00 derived: sum of 4 quarters · filed 2025-03-18 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-03-18 | $0.00 derived: sum of 3 quarters · filed 2025-03-18 | $0.00 derived: sum of 4 quarters · filed 2025-03-18 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $0.00 derived: sum of 2 quarters · filed 2025-03-18 | $0.00 derived: sum of 3 quarters · filed 2025-03-18 | $0.00 10-K · filed 2025-03-18 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |